Effects of Long-acting Insulin Analogues on Breast and Colon Cancer Promotion

dc.contributor.advisorGiacca, Adria
dc.contributor.authorKo, Eunhyoung
dc.contributor.departmentPhysiologyen_US
dc.date2014-03en_US
dc.date.accessioned2016-03-09T15:50:08Z
dc.date.availableWITHHELD_TWO_YEARen_US
dc.date.available2016-03-09T15:50:08Z
dc.date.issued2014-03
dc.description.abstractInsulin glargine, a long-acting insulin analogue, has been implicated in increased cancer risk by epidemiological studies and has been reported to increase mitogenicity in in vitro studies. However, studies in preclinical models confirming the tumor promoting effect of glargine are lacking. Methylnitrosourea and azoxymethane treated female Sprague-Dawley rats were randomly assigned to receive saline, neutral protamine Hagedorn (NPH, unmodified insulin), glargine, or detemir (long-acting insulin analogues) for 6 weeks (30/group). Rats treated with NPH had significantly higher mammary tumour multiplicity and a tendency to increased tumour incidence. Mammary tumour burden tended to increase in all insulin-treated rats compared to control. There was no effect of insulin on aberrant crypt foci, a precursor of colon cancer, compared to control. These data suggest that glargine does not promote breast or colon cancer to a greater extent than unmodified insulin. This is important information in the management of patients with diabetes.en_US
dc.description.degreeMASTen_US
dc.identifier.urihttp://hdl.handle.net/1807/71547
dc.language.isoen_caen_US
dc.subjectInsulin analoguesen_US
dc.subjectBreast Canceren_US
dc.subjectColon Canceren_US
dc.subject.classification0719en_US
dc.titleEffects of Long-acting Insulin Analogues on Breast and Colon Cancer Promotionen_US
dc.typeThesisen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ko_Eunhyoung_201403_Msc_thesis.pdf
Size:
1.64 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2 KB
Format:
Item-specific license agreed upon to submission
Description: